The US net sales increased 5% to $3.3bn in the first quarter of 2011 compared to the same period in 2010.
International net sales increased 3%, or 1% excluding foreign exchange impact, to $1.8bn.
The company’s global sales growth in the first quarter was led by Plavix (6%), recently launched Onglyza and Kombiglyze, Baraclude (27%), Sprycel (31%) and Orencia (18%).
The GAAP net earnings were $986m, or $0.57 per share, in the first quarter of 2011 compared to $743m or $0.43 per share for the same period in 2010.
Bristol-Myers Squibb CEO Lamberto Andreotti said they delivered solid financial performance at both the top and bottom lines, received regulatory approval for Yervoy in the US, received a positive advisory opinion from European regulatory authorities for both Eliquis and Nulojix, and presented promising data on our investigational hepatitis C portfolio at the annual meeting of the European Association for the Study of the Liver.